D-enantiomer of DFMO and methods of use therefor
AssigneeILEX Oncology, Inc.
InventorsCorey Levenson, Ze'ev Shaked
Life of this patent
Estimating the term…
Abstract
The present invention concerns a method for preventing and/or treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine (D-DFMO) or an analog of D-DFMO to the patient. D-DFMO or an analog thereof is administered at a dose of about 0.05 to about 20.0 gm/M2/day. D-DFMO or an analog thereof may be administered more than once for the treatment and/or prevention of cancer. Methods of administration as well as compositions and formulations of substantially purified D-DFMO and analogs of D-DFMO are described.
Claims33
A method for preventing and/or treating a tumor sensitive to difluoromethylornithine (DFMO) in a patient in need thereof comprising administering an effective amount of substantially enriched D enantiomer of DFMO (D-DFMO) or an analog thereof to said patient and wherein the substantially enriched D enantiomer comprises at least 70% by weight of the total difluoromethylornithine or analog and wherein the enriched D enantiomer has reduced ototoxicity.
A pharmaceutical composition, comprising substantially enriched D enantiomer of difluoromethylornithine (D-DFMO) or analog thereof together with a pharmaceutically acceptable carrier and wherein the substantially enriched D enantiomer comprises at least 70% by weight of the total difluoromethylornithine or analog and wherein the enriched D enantiomer has reduced ototoxicity.
Dependencies are inferred from the claim text.